AVITA Medical Schedules Third Quarter 2026 Financial Results Announcement
AVITA Medical has scheduled the release of its financial results for the third quarter of 2026.
Stocks · News reference
BTIG Maintains Buy on AVITA Medical, Raises Price Target to $15
BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $11 to $15.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AVITA Medical Q2 2026 Earnings Call Transcript
On Thursday, AVITA Medical (NASDAQ:RCEL) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call transcripts
TD Cowen Maintains Buy on AVITA Medical, Raises Price Target to $14
TD Cowen analyst Joshua Jennings maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $12 to $14.